Group 1 - The core patent of Dongyangguang Pharmaceutical's invention "Bridge cyclic compound as a hepatitis C inhibitor and its preparation method" has won the second Hubei Patent Gold Award, highlighting the company's innovation and core competitiveness in new drug development [1][5][12] - The hepatitis C virus (HCV) infection rate in China is approximately 10 million, with new reported cases around 200,000 per year, indicating a significant public health challenge due to low diagnosis and treatment rates [6][7] - Dongyangguang Pharmaceutical established its research goal in 2010 to develop hepatitis C drugs tailored for the Chinese market, aiming to provide effective treatment options for the large patient population [6][7] Group 2 - The drug, Phosphoric acid imetavine, was developed over ten years and became the first domestically developed hepatitis C NS5A inhibitor in China, receiving approval in 2020 [7][8] - Phosphoric acid imetavine has a high overall cure rate of 99.8% when used in combination with Sofosbuvir, and it was included in the national medical insurance directory in December 2021, significantly reducing the cost for patients [7][8] - The patent strategy for Phosphoric acid imetavine includes a comprehensive layout that began in 2013 and has expanded to cover various aspects of the drug, enhancing its market competitiveness and protecting its innovations [10][11] Group 3 - Since its establishment in 2001, Dongyangguang Pharmaceutical has focused on R&D, applying for over 2,400 invention patents and holding more than 1,400 authorized patents, making it a leader in patent filings among domestic pharmaceutical companies [12] - The company has built a complete innovation chain from basic research to clinical transformation, with 150 approved drugs globally and over 100 in development, including nearly 50 first-class innovative drugs [12] - Dongyangguang Pharmaceutical aims to continue driving development through innovation, enhancing its core competitiveness, and contributing to the high-quality development of the pharmaceutical industry [12]